Immix Biopharma, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$30.0M | -$22.7M | -$16.1M | -$8.2M | -$1.4M |
| Operating expenses | $30.0M | $22.7M | $16.1M | $8.2M | $1.4M |
| Cash from operations | -$23.9M | -$14.6M | -$11.4M | -$7.4M | -$1.6M |
| Capital expenditure | $732,925 | $1.2M | $52,089 | — | $802 |
| Free cash flow | -$24.7M | -$15.8M | -$11.4M | — | -$1.6M |
| Share repurchases | — | — | — | $99,963 | — |
| Total assets | $104.8M | $22.9M | $19.9M | $14.9M | $18.2M |
| Total liabilities | $11.0M | $9.7M | $3.7M | $1.7M | $202,039 |
Shares outstanding 54.4M · Free float 78.8%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.